Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes

Ejemplares similares

• Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real‐world analysis
  por: Satish K. Garg, et al.
  Publicado: (2024)
• Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
  por: Paschalis Karakasis, et al.
  Publicado: (2024)
• Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
  por: Jincheng Shen, et al.
  Publicado: (2025)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  por: Filip K. Knop, et al.
  Publicado: (2024)
• Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist
  por: Luděk Horváth, et al.
  Publicado: (2025)